Holen Sie sich die Stockscreener-App
12.32
1.52%
-0.1829
Schlusskurs vom Vortag:
$12.50
Offen:
$12.64
24-Stunden-Volumen:
1.07M
Relative Volume:
0.47
Marktkapitalisierung:
$1.96B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-9.1238
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
+6.30%
1M Leistung:
+28.10%
6M Leistung:
+62.62%
1J Leistung:
+47.07%
1-Tages-Spanne:
$12.25
$12.65
1-Wochen-Bereich:
$10.58
$12.65
52-Wochen-Spanne:
$5.80
$12.65
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.31 | 1.91B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.32 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.41 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.62 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.49 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
295.87 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call Transcript - MSN
Ocular Therapeutix stock hits 52-week high at 12.38 USD - Investing.com
Ocular Therapeutix: Q2 Earnings Snapshot - Huron Daily Tribune
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Ocular Therapeutix 2025 Q2 Earnings Deepening Losses Amid Strategic Momentum - AInvest
Ocular Therapeutix Reports Second Quarter 2025 Financial Results - VisionMonday.com
Ocular Therapeutix Reports Q2 2025 Financial Results - TipRanks
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
OCUL Sales Drop 18% - The Motley Fool
Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress - TipRanks
Ocular Therapeutix Q2 2025: Unpacking Key Contradictions in SOL-R Trial Criteria and FDA Relations - AInvest
Ocular Therapeutix stock maintains Buy rating at TD Cowen ahead of Phase III data - Investing.com Canada
Ocular Therapeutix Q2 2025 Earnings Call Transcript - MarketBeat
Clear Street reiterates Buy rating on Ocular Therapeutix stock at $18 - Investing.com Canada
Raymond James reiterates Strong Buy on Ocular Therapeutix stock with $19 target - Investing.com Canada
Earnings call transcript: Ocular Therapeutix misses Q2 2025 earnings, stock drops - Investing.com
Ocular Therapeutix Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocular Therapeutix tumbles as Q2 results miss estimates - Investing.com
Ocular Therapeutix: Can AXPAXLI's Pipeline Offset Financial Headwinds? - AInvest
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Ocular Therapeutix Inc earnings missed by $0.04, revenue fell short of estimates - Investing.com
Ocular Therapeutix Reports Second Quarter 2025 Financial Results and Business Highlights - TradingView
Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
OCULAR THERAPEUTIX, INC SEC 10-Q Report - TradingView
Ocular Therapeutix raises $97mln, expects cash runway into 2028. - AInvest
What's Next: Ocular Therapeutix's Earnings Preview - 富途牛牛
Ocular Therapeutix stock maintains Strong Buy rating at Raymond James By Investing.com - Investing.com Canada
Ocular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
What analysts say about Ocular Therapeutix Inc. stockBuild wealth with high-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. a growth stock or a value stockHigh-yield investments - Jammu Links News
When is Ocular Therapeutix Inc. stock expected to show significant growthAchieve impressive returns with smart timing - Jammu Links News
What are the latest earnings results for Ocular Therapeutix Inc.Capitalize on market shifts with expert advice - Jammu Links News
How does Ocular Therapeutix Inc. compare to its industry peersBreakout stock performance - Jammu Links News
How does Ocular Therapeutix Inc. generate profit in a changing economyInvest confidently with data-backed picks - Jammu Links News
Is it the right time to buy Ocular Therapeutix Inc. stockTriple-digit growth rates - Jammu Links News
Should I hold or sell Ocular Therapeutix Inc. stock in 2025Capitalize on market trends with expert guidance - Jammu Links News
How volatile is Ocular Therapeutix Inc. stock compared to the marketBuild a diversified portfolio for steady profits - Jammu Links News
What are Ocular Therapeutix Inc. company’s key revenue driversGet daily updates on top-performing stocks - Jammu Links News
Is Ocular Therapeutix Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
What is Ocular Therapeutix Inc. company’s growth strategyAchieve rapid portfolio appreciation - Jammu Links News
How strong is Ocular Therapeutix Inc. company’s balance sheetExtraordinary performance - Jammu Links News
Does Ocular Therapeutix Inc. stock perform well during market downturnsLow Risk Guidance That Work - jammulinksnews.com
Identifying reversal signals in Ocular Therapeutix Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Using data filters to optimize entry into Ocular Therapeutix Inc.Risk Managed Intraday Trade Alerts Increase in Volume - metal.it
Quantitative breakdown of Ocular Therapeutix Inc. recent moveReliable Alerts for Daily Stock Movers Released - metal.it
Ocular Therapeutix Inc. Reaches Critical Trendline SupportTrend Analysis for Safer Trades Gains Popularity - metal.it
Can Ocular Therapeutix Inc. Rally Enough to Break EvenTechnical Entry Strategy for Beginners Explained - metal.it
Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewswire
After Leaping 31% Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Are Not Flying Under The Radar - simplywall.st
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
1.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):